Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
COSMOS Pharma, Jun-Feb (Cumulative 3Q) Ordinary Profit Increases by 30%, Dec-Feb Ordinary Profit Increases by 40%
3349 COSMOS Pharmaceutical Corporation 【J-GAAP】
Earnings ReportCOSMOS Pharmaceutical Corporation <3349> [TSE Prime] announced its financial results after the market closed on April 14th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending May 2025 (June 2024 to February 2025) expanded 33.7 billion yen, an increase 30.3% compared to the same period last year. The progress rate toward the full-year plan of 34.4 billion yen was 98.2%, also surpassing the five-year average of 73.5%.
Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the March to May period (4Q) is expected to significant drop 92.5% from the same period last year to 0.62 billion yen.
In the most recent three-month period, from December to February (3Q), the consolidated ordinary profit increased 40.0% from the same period last year, reaching 11.9 billion yen. The operating profit margin improved from 3.3% in the same period last year to 4.6%.
Kabutan News
Actual Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Jun - Feb, 2022 | 606,302 | 22,167 | 24,393 | 16,283 | 205.6 | 73.7 | Apr 10, 2023 | J-GAAP |
Jun - Feb, 2023 | 715,311 | 23,738 | 25,914 | 17,357 | 219.1 | 75.6 | Apr 12, 2024 | J-GAAP |
Jun - Feb, 2024 | 752,268 | 31,627 | 33,771 | 22,343 | 281.9 | 98.2 | Apr 14, 2025 | J-GAAP |
YoY | +5.2% | +33.2% | +30.3% | +28.7% | +28.7% |
Current Period Guidance
Second Half Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec - May, 2023 | 488,559 | 15,665 | 16,953 | 12,867 | 162.4 | 30 | Jul 12, 2024 | J-GAAP |
Dec - May, 2024 Guidance | 531,064 | 11,256 | 12,623 | 10,072 | 127.1 | 32.50 | Jan 10, 2025 | J-GAAP |
YoY | +8.7% | -28.1% | -25.5% | -21.7% | -21.7% |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
May, 2023 | 827,697 | 30,128 | 33,086 | 23,797 | 300.5 | 50 | Jul 10, 2023 | J-GAAP |
May, 2024 | 964,989 | 31,501 | 34,299 | 24,454 | 308.6 | 60 | Jul 12, 2024 | J-GAAP |
May, 2025 Guidance | 1,037,000 | 31,600 | 34,400 | 24,500 | 309.1 | 65 | Jul 12, 2024 | J-GAAP |
YoY | +7.5% | +0.3% | +0.3% | +0.2% | +0.2% |
Quarterly Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec - Feb, 2023 | 238,881 | 7,902 | 8,568 | 5,770 | 72.8 | 3.3 | Apr 12, 2024 | J-GAAP |
Mar - May, 2024 | 249,678 | 7,763 | 8,385 | 7,097 | 89.6 | 3.1 | Jul 12, 2024 | J-GAAP |
Jun - Aug, 2024 | 261,841 | 11,580 | 12,293 | 8,143 | 102.7 | 4.4 | Oct 11, 2024 | J-GAAP |
Sep - Nov, 2024 | 244,095 | 8,764 | 9,484 | 6,285 | 79.3 | 3.6 | Jan 10, 2025 | J-GAAP |
Dec - Feb, 2024 | 246,332 | 11,283 | 11,994 | 7,915 | 99.9 | 4.6 | Apr 14, 2025 | J-GAAP |
YoY | +3.1% | +42.8% | +40.0% | +37.2% | +37.1% |
Related Articles
SMN, Last Fiscal Year Net Income Revised Upward by 93%
DOUTOR NICHIRES, 12% Increase in Ordinary Profit, Record High for The First Time in Nine Years, Increased Previous Year's Dividend by 2 yen, This Fiscal Year to Increase Dividend by 4 yen
DEMAE-CAN, First Half Ordinary Profit Loss Narrows, Dec-Feb Ordinary Profit Loss Narrows
Copa Corp, Net Income/Loss Unexpectedly Turn to Loss for Last Fiscal Year, The Current Fiscal Year's Net Income to Narrow
STUDIO ALICE, 6% Decrease in Ordinary Profit for The Current Fiscal Year
FP Partner, Dec-Feb (1Q) Ordinary Profit Decreases by 42%
DIP, 10% Decrease in Ordinary Profit for The Current Fiscal Year
Totenko, 2% Increase in Ordinary Profit for The Current Fiscal Year
Asterisk, The Current Fiscal Year Ordinary Profit Revised Downward by 82%
Maruto Sangyo, 15% Increase in Ordinary Profit for The Current Fiscal Year